Kazuki Tanaka

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Kazuki Tanaka, Brigitte Adams, Álvaro Madrid Arís et al. · Pediatric Nephrology · 2020 · 72 citations · Full text

Pleosporales in Japan (2): the genus Lophiotrema

Kazuki Tanaka, Yukio Harada · Mycoscience · 2003 · 47 citations

Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling

Anna Nakamura, Yoko Yokoyama, Kazuki Tanaka et al. · iScience · 2020 · 35 citations · Full text

Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol

Satoshi Hibino, Osamu Uemura, Takuhito Nagai et al. · Pediatrics International · 2014 · 16 citations

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan

Shuichi Ito, Hiroshi Hataya, Akira Ashida et al. · Nephrology Dialysis Transplantation · 2022 · 15 citations · Full text